A prospective survey on safety of sustained-release theophylline in treatment of asthma and COPD

Allergology International

Volumn 55, Issue 4, 2006, Pages 395-402

  Makino, Sohei ^a,b   Adachi, Mitsuru ^a   Ohta, Ken ^a   Kihara, Norio ^a   Nakajima, Sigenori ^a   Nishima, Sankei ^a   Fukuda, Takeshi ^a   Miyamoto, Terumasa ^a  

^a Japanese Society of Allergology   (Japan)

^b Jobu Hospital for Respiratory Disease   (Japan)

Author keywords

Adverse drug reactions; Asthma; COPD; Safety evaluation; Sustained release; Theophylline

Indexed keywords

ANTIALLERGIC AGENT; CORTICOSTEROID DERIVATIVE; MACROLIDE; METHYLXANTHINE DERIVATIVE; QUINOLONE DERIVATIVE; THEOPHYLLINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APPETITE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BLOATING; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DYSPEPSIA; FEMALE; HEART PALPITATION; HUMAN; HYPERURICEMIA; HYPESTHESIA; INCIDENCE; INDIGESTION; INSOMNIA; JAPAN; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL SOCIETY; METABOLIC DISORDER; MUSCLE HYPERTONIA; NAUSEA; NUTRITIONAL DISORDER; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN DISEASE; SUSTAINED DRUG RELEASE; TREMOR; URIC ACID BLOOD LEVEL; VOMITING;

EID: 33846051559     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.55.395     Document Type: Article

References (27)

1. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am. J. Respir. Crit. Care Med. 1995;151:1907-1914.
2. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-1008.
3. Jaffar ZH, Sullivan P, Page C, Costello J. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur. Respir. J. 1996;9:456462.
4. Lim S, Tomita K, Carramori G et al. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am. J. Respir. Crit. Care Med. 2001;164:273-276.
5. Ohta K, Sawamoto S, Nakajima M et al. The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis. Clin. Exp. Allergy 1996;26:10-15.
6. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J. Clin. Invest. 1997; 100:1677-1684.
7. Ito K, Lim S, Caramori G et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. U.S.A. 2002;99:8921-8926.
8. Mitenko PA, Ogilvie RI. Rational intravenous doses of theophylline. N. Engl. J. Med. 1973;289:600-603.
9. Makino S, Furusyo K, Miyamoto T, Ohta K. Asthma prevention and management guidelines 1998, Japan (JGL 1998). Int. Arch. Allergy Immunol. 2000;121:1-78.
10. National Heart, Lung, and Blood Institute, National Institutes of Health. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report, Global Initiative for Asthma (GINA 1995). Publication no.93-3659. Bethesda: National Institutes of Health, 1995.
11. The Japanese Respiratory Society Guidelines for the Diagnosis and Management of COPD. 2005.
12. National Heart, Lung, and Blood Institute, National Institutes of Health. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop Report. Global Initiative for Chronic Obstructive Lung Disease. Bethesda: National Institutes of Health, 2005.
13. ICH Harmonised Tripartite Guideline (EMEA Status as of November 1994). Clinical safety data management: Definitions and standards for expedited reporting.
14. Takishima T, Mue Y, Sasaki H. [Clinical evaluation of sustained release theophylline (MCI-8019) on chronic obstructive pulmonary disease.] Yakuri to Chiryo 1986;14: 4915-4934 (in Japanese).
15. Miyamoto T, Takishima T, Satake T, Kabe J. [Studies for the guideline concerning clinical dosage and administration in the "round the clock" therapy by theophylline for bronchial asthma: I. Optimal dose finding study of E-0686 tablet, a new sustained-release theophylline preparation, in adult patients.] Kokyu 1985;4:861-876 (in Japanese).
16. Harasawa M, Shinda T, Miyamoto T, Takahashi T, Kabe J, Nakajima S. [Study to evaluate the guidelines for determination of the optimal dosage for NI-102S, a sustained-release theophylline preparation, in adult bronchial asthma.] Rinsho Iyaku 1992;8:95-129 (in Japanese).
17. Weinberger MM. Methyxanthines. In: Weisss EB, Stein M (eds). Bronchial asthma: mechanisms and therapeutics, 3rd edn. Little, Brown and Company Inc., 1993;764-783.
18. Milavetz G, Vaughan LM, Weinberger MM, Hendeles L. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. J. Pediatr. 1986;109:351-354.
19. Minoguchi K, Kohno Y, Oda K et al. Effect of theophylline withdrawal on airway inflammation in asthma. Clin. Exp. Allergy 1998;28:57-63.
20. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma: Demonstration by withdrawal of therapy. Am. J. Respir. Crit. Care Med. 1995;151:1907-1914.
21. Reed CE, Offord KP, Nelson HS, Li JT, Tinkelman DG. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-moderate asthma. J. Allergy Clin. Immunol. 1998;101:14-23.
22. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N. Engl. J. Med. 1997; 337:1412-1418.
23. Ukena D, Harnest U, Sakalauskas R et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur. Respir. J. 1997;10:2754-2760.
24. Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes PJ. Comparison of high dose inhaled steroids, low dose inhaled steroid plus low dose theophylline, and low-dose inhaled steroids alone in chronic asthma. Thorax 2000;55:837-841.
25. Rivington RN, Boulet L-P, Cate J et al. Efficacy of uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am. J. Respir. Crit. Care Med. 1995;151:325-332.
26. Reisz G, Pingleton SK, Melethil S, Ryan PB. The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. Am. Rev. Respir. Dis. 1983;127:581-584.
27. National Heart, Lung, and Blood Institute, National Institutes of Health. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report Revised Global Initiative for Asthma (GINA 2002). Publication no. 02-3659. Bethesda: National Institutes of Health, 2002.